Promoted Content
Promoted Content

Find Clinical Drug Pipeline Developments & Deals by Diurnal Group

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
Therapeutic Area filter
    Study Phase filter
      Country filter
        News Type filter
          Company filter
            refresh

            Companies By Therapeutic Area Full Screen

            Development Status Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Hydrocortisone

            Therapeutic Area: Endocrinology Product Name: Alkindi

            Highest Development Status: Approved Product Type: Small molecule

            Recipient: EffRx Pharmaceuticals

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable October 23, 2020

            Details:

            EffRx anticipates a potential market launch for Alkindi in Switzerland by 2022 and will receive the exclusive rights to market and sell the product in Switzerland once the product has been registered.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Hydrocortisone

            Therapeutic Area: Endocrinology Product Name: Alkindi

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: EffRx

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Licensing Agreement October 21, 2020

            Details:

            Under the terms of the agreement EffRx has received the exclusive rights to register and commercialize Alkindi® in Switzerland.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Hydrocortisone

            Therapeutic Area: Endocrinology Product Name: Undisclosed

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Eton Pharmaceuticals

            Deal Size: $7.5 million Upfront Cash: $3.5 million

            Deal Type: Licensing Agreement March 27, 2020

            Details:

            The acquisition advanced Eton’s leadership in pediatric rare diseases products providing a $100 million market opportunity.